Φορτώνει......
Organoid technology for personalized pancreatic cancer therapy
BACKGROUND: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. P...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cell Oncol (Dordr) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Netherlands
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7985124/ https://ncbi.nlm.nih.gov/pubmed/33492660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-021-00585-1 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|